News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Guggenheim.

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phathom Pharmaceuticals Announces Leadership Succession

3/6/2025

08:00 am

PHAT

-3.9%

BEAT

3/6/2025

08:00 am

PHAT

-3.3%

BEAT

3/6/2025

08:00 am

PHAT

-7.8%

BEAT

3/6/2025

08:00 am

PHAT

-8.5%

BEAT

Needham & Company LLC

Form 4 Phathom Pharmaceuticals, For: Apr 03 Filed by: Basta Steven L

Form 3 Phathom Pharmaceuticals, For: Apr 01 Filed by: Basta Steven L

Form S-8 Phathom Pharmaceuticals,

Form 8-K Phathom Pharmaceuticals, For: Mar 31

Form 4 Phathom Pharmaceuticals, For: Sep 10 Filed by: Parikh Asit

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}